Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor–treated rheumatoid arthritis patients

Philip D H Hamann,John D. Pauling,Neil McHugh,Gavin Shaddick,Kimme L. Hyrich,Nicola Maiden,Thomas B. Price,Neil Hopkinson,Sheila O'Reilly,Lesley Hordon,Id. Griffiths,Duncan Porter,Hilary A Capell,Andrew Hassell,Romela Benitha,Ernest Choy,David A. Walsh,Paul Emery,Susan Knight,Ian N. Bruce,A. J. Taggart,David Scott,Bev Harrison,Paul D. Thompson,Fiona McCrae,Rhian Mair Goodfellow,Marwan Bukhari,Peter Klimiuk,George D. Kitas,Ronald Jubb,Rikki Abernethy,Shane Clarke,Sandra Green,P.A. Sanders,Amanda Coulson

Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor–treated rheumatoid arthritis patients

2019

Objectives To investigate the frequency and predictors of sustained 28-joint DAS (DAS28) remission and low disease activity (LDA) in patients receiving anti-TNF therapy and changes in responses over a 12 year period.

Keywords:

Diabetes mellitus
Sustained remission
Physical therapy
Rheumatoid arthritis
Disease
Demographics
Internal medicine
Necrosis
Medicine
Rheumatology
Etanercept
Adalimumab
Logistic regression
Infliximab
Epidemiology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations